Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie lub cytologicznie nowotwór jajnika, otrzewnej lub jajowodu
- •Rak jajnika wrażliwy na platynę - progresja choroby pojawiła się co najmniej 6 miesięcy po pierwszej chemioterapii
- •Dla pacjentów z mutacją BRCA lub defektem rekombinacji homologicznej - wcześniejsze leczenie inhibitorem PARP
- •Ukończona chemioterapia drugiej linii leczenia
- •Rozpoczęcie badania nie później niż 8 tygodni od ostatniej dawki chemioterapii
✗ Disqualifies
- •Inne typy histologiczne raka jajnika (jasnokomórkowy, śluzowy, sarkomatoidalny)
- •Więcej niż 2 poprzednie linie leczenia systemowego
- •Postęp choroby podczas lub po drugiej linii chemioterapii
- •Przyjęcie innego leczenia przeciwnowotworowego między chemioterapią a włączeniem do badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 16, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (16)
Mt. Sinai Comprehensive Cancer Center
Miami, United States
Sarasota Memorial Health Care System
Sarasota, United States
Miami Valley Hospital South
Centerville, United States
Zangmeister Cancer Center
Columbus, United States
National Hospital Organization Hokkaido Cancer Center
Sapporo, Japan
Sapporo Medical University Hospital
Sapporo, Japan
Hyogo Cancer Center
Akashi, Japan
Mie University Graduate School Of Medicine
Tsu, Japan
Osaka Medical and Pharmaceutical University Hospital
Takatsuki, Japan
Saitama Medical University International Medical Center
Hidaka, Japan
The Jikei University Kashiwa Hospital
Kashiwa, Japan
Niigata University Medical & Dental Hospital
Niigata, Japan
Okayama University Hospital
Okayama, Japan
Kitasato University Hospital
Sagamihara, Japan
The Cancer Institute Hospital of JFCR
Tokyo, Japan
Kanagawa Prefectural Cancer Center
Yokohama, Japan
Trial contact
Genmab Trial Information
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.